Pokriva li osiguranje Wegovy? Ovisi — evo kako to brzo saznati.

Kratki odgovor

U nastavku ćemo proći kroz svakog većeg osiguravatelja — što obično pokrivaju, koju dokumentaciju za prethodno odobrenje traže i što učiniti ako prvi put kažu ne. Pravila pokrića stalno se mijenjaju, stoga uvijek potvrdite sa svojim konkretnim planom prije donošenja odluka. Nijedan podatak ovdje nije jamstvo da će bilo koji konkretan plan pokriti Wegovy za bilo kojeg konkretnog pacijenta.

Pokriva li Wegovy većina planova osiguranja?

Iskren odgovor je da ga pokriva više planova nego prije tri godine, ali pokriće je i dalje nedosljedno i u nekim segmentima sve teže dobiti. Kada je Wegovy prvi put lansiran 2021., velika većina osiguravatelja isključivala je lijekove za mršavljenje kao kategoriju. Otad su se promijenile dvije stvari: baza kliničkih dokaza narasla je do te mjere da se lijekovi protiv pretilosti sve više tretiraju kao standard skrbi, a FDA-ina kardiovaskularna indikacija iz 2024. stvorila je drugi put do pokrića koji uopće ne ovisi o isključenju pretilosti.

Istodobno se pojačao pritisak troškova na planove. Wegovy i Zepbound sada su među najvišim kategorijama farmaceutske potrošnje za mnoge velike poslodavce. Neki planovi koji su nekad velikodušno pokrivali Wegovy otad su dodali postupnu terapiju, snizili godišnja količinska ograničenja ili potpuno izbacili mršavljenje iz svoje liste lijekova. Oba smjera događaju se istodobno.

Razumno pravilo za 2026.:

• Komercijalni planovi velikih poslodavaca: Otprilike 50-60% uključuje Wegovy na listu lijekova, gotovo uvijek uz prethodno odobrenje.
• Planovi malih poslodavaca i individualni tržišni planovi: Pokriće je rjeđe, možda 30-40%, a isključenja su češća.
• Medicare Advantage i Part D: Isključeno za mršavljenje; dopušteno samo za kardiovaskularnu indikaciju.
• Medicaid: Pokriće postoji u otprilike 13 saveznih država za pretilost; većina država i dalje isključuje.
• Tricare: Općenito nije pokriveno za mršavljenje.
• Samofinancirajući planovi poslodavaca (ERISA): Iznimno promjenjivo. Bira poslodavac, ne osiguravatelj. Neke tvrtke s liste Fortune 500 pokrivaju velikodušno; druge potpuno isključuju.

Najkorisnije što možete učiniti jest nazvati broj članske službe na poleđini svoje kartice osiguranja i pitati: „Je li semaglutid za kronično upravljanje tjelesnom težinom — Wegovy — na mojoj listi lijekova i kakav je postupak prethodnog odobrenja?" Ako je moguće, zatražite odgovor u pisanom obliku.

Pokriće Wegovyja po većim osiguravateljima

Tablica u nastavku sažima kako veći američki osiguravatelji obično postupaju s pokrićem Wegovyja. Zapamtite da unutar svakog osiguravatelja stvarna polica ovisi o vašem konkretnom planu, saveznoj državi i (za pokriće koje sponzorira poslodavac) o izborima dizajna plana vašeg poslodavca.

Slijede detaljne napomene o svakom većem osiguravatelju. Nijedan od ovih opisa ne jamči pokriće na vašem konkretnom planu — oni opisuju tipične obrasce koje vidimo u dokumentima liste lijekova, biltenima politika planova i iskustvima pacijenata početkom 2026.

UnitedHealthcare

UnitedHealthcare je najveći komercijalni zdravstveni osiguravatelj u SAD-u, a velik udio njegovih komercijalnih planova pokriva Wegovy. UnitedHealthcare obično navodi Wegovy u razini 3 (nepreferirani brend) svoje standardne liste lijekova na recept (PDL) i zahtijeva prethodno odobrenje putem OptumRx-a, svog internog upravitelja farmaceutskih pogodnosti. Tipični kriteriji UHC-a uključuju dokumentiran BMI od 30 ili više (ili 27 uz stanje povezano s tjelesnom težinom), dokumentaciju o najmanje 6 mjeseci pokušaja prehrane i tjelovježbe te izjavu da pacijent nema kontraindikacija.

Komercijalni planovi UnitedHealthcarea obično odobravaju početno prethodno odobrenje na 6 do 12 mjeseci, a zatim zahtijevaju ponovno odobrenje koje dokumentira napredak u mršavljenju (obično barem 5% gubitka tjelesne težine) prije produljenja pokrića. Nemogućnost dokazivanja napretka najčešći je razlog zbog kojeg prethodno odobreni pacijent gubi pokriće pri obnovi. Planovi UnitedHealthcare Medicare Advantage i većina Medicaid planova upravljane skrbi pod brendom UnitedHealthcare ne pokrivaju Wegovy za mršavljenje, iako ga Medicare Advantage Part D može pokriti za kardiovaskularnu indikaciju kod podobnih pacijenata.

Aetna

Aetna, sada dio CVS Healtha, pokriva Wegovy na većini komercijalnih lista lijekova u razini 3 uz prethodno odobrenje putem CVS Caremarka. Aetnina objavljena politika za lijekove protiv pretilosti detaljnija je od većine osiguravatelja i obično zahtijeva isti prag BMI-ja/komorbiditeta kao FDA-ina naljepnica, plus dokumentaciju o strukturiranom programu mršavljenja (poput komercijalnog programa, ovlaštenog dijetetičara ili plana pod nadzorom liječnika).

Aetna je također jedan od osiguravatelja koji najvjerojatnije primjenjuje postupnu terapiju. Neki Aetnini planovi zahtijevaju da su pacijenti prvo isprobali Saxendu (liraglutid), stariji GLP-1 istog proizvođača, ili drugi pokriveni lijek protiv pretilosti, te da s njim nisu uspjeli ili su imali nepodnošljive nuspojave, prije odobravanja Wegovyja. Ako imate dokumentiran prethodni neuspjeh s drugim lijekom protiv pretilosti, pobrinite se da ga vaš zdravstveni djelatnik uključi u zahtjev za prethodno odobrenje — to gotovo uvijek ubrzava odobrenje. Samofinancirajući planovi poslodavaca kod Aetne mogu potpuno isključiti lijekove za mršavljenje; to je izbor dizajna plana, a ne Aetnina odluka.

Blue Cross Blue Shield (BCBS) i Anthem

Blue Cross Blue Shield nije jedan osiguravatelj — riječ je o udruženju od 33 neovisne, lokalno vođene tvrtke (BCBS Massachusetts, BCBS Texas, Highmark, Independence Blue Cross, Horizon BCBS New Jersey, BCBS Illinois i tako dalje). Pokriće Wegovyja razlikuje se među BCBS planovima više nego kod bilo kojeg drugog brenda osiguravatelja jer svaki nositelj licence postavlja vlastitu listu lijekova.

Neki BCBS planovi (Federal Employee Program BCBS, nekoliko velikih Blue planova koje sponzoriraju poslodavci) pokrivaju Wegovy u razini 3 uz prethodno odobrenje. Drugi su donijeli javno istaknute odluke o ukidanju ili ograničavanju pokrića lijekova za mršavljenje. BCBS Massachusetts, primjerice, najavio je 2024. da će ograničiti GLP-1 lijekove za mršavljenje na određenim planovima zbog pritiska troškova, a planovi za državne službenike BCBS North Carolina prošli su sličan pregled. Uvijek provjerite konkretan BCBS subjekt koji je izdao vašu karticu — troslovni prefiks na vašem članskom ID-u obično identificira plan koji ga je izdao.

Anthem, koji djeluje kao BCBS nositelj licence u 14 saveznih država (Kalifornija, New York, Ohio, Indiana, Virginia, Colorado i druge), ima vlastitu politiku lijekova protiv pretilosti. Većina komercijalnih planova Anthema pokriva Wegovy u razini 3 uz prethodno odobrenje, a Anthem je jedan od osiguravatelja koji najvjerojatnije zahtijeva 6 mjeseci dokumentirane promjene načina života prije odobravanja prethodnog odobrenja. Anthem obično zahtijeva da ova dokumentacija dolazi iz bilješki ordinacije zdravstvenog djelatnika — usmena povijest sama po sebi nije dovoljna.

Cigna

Cigna covers Wegovy on select commercial formularies through Express Scripts (its in-house PBM) with prior authorization. Cigna's published criteria are similar to other major insurers — BMI ≥30 or ≥27 with comorbidity, documented weight loss attempts, and absence of contraindications. Cigna is somewhat more likely than UHC or Aetna to apply quantity limits, restricting patients to a 28- or 30-day supply per fill rather than a 90-day supply, which can be inconvenient for patients on stable maintenance doses.

Cigna's criteria for the cardiovascular indication require documentation of established cardiovascular disease (prior heart attack, stroke, peripheral artery disease, or similar) along with the obesity diagnosis. If you qualify under both indications, your prescriber should reference both in the prior authorization to maximize the chance of approval.

Kaiser Permanente

Kaiser Permanente is an integrated payer-provider, meaning the prescribing decision and the formulary decision are made within the same organization. Kaiser's coverage of Wegovy varies significantly by region — Kaiser Northern California, Southern California, Mid-Atlantic, Colorado, Northwest, Hawaii, and Washington each set their own formulary policies.

In some Kaiser regions, Wegovy is available through the Kaiser weight management program with prior authorization but only after enrollment in a structured medical weight loss program that includes dietitian visits and behavioral counseling. Other regions are more restrictive. Because Kaiser dispenses through its own pharmacies, there is no off-network option to fill a Kaiser prescription elsewhere using the Kaiser benefit. If your Kaiser plan does not cover Wegovy and you want to access it, you would either need to pay out of pocket at NovoCare or pursue a separate prescription outside the Kaiser system.

Humana

Humana is primarily a Medicare Advantage carrier, which means most Humana enrollees fall under the Medicare Part D rules for weight loss medications — generally not covered. Humana commercial plans (a smaller portion of its book of business) handle Wegovy similarly to other commercial insurers, with prior authorization required.

For Humana Medicare Advantage members, the same cardiovascular indication exception applies that applies to all Medicare Part D plans: Wegovy may be covered when prescribed for reducing the risk of major adverse cardiovascular events in members with obesity and established cardiovascular disease. Prior authorization for that indication typically requires documentation of a qualifying cardiovascular event in the patient's medical history.

Medicare coverage of Wegovy

Medicare's relationship with Wegovy is unique and worth understanding in detail. There is a hard statutory rule and there is a 2024 exception, and they interact in ways that confuse a lot of patients.

The statutory exclusion

Section 1860D-2(e)(2)(A) of the Social Security Act, originally enacted as part of the Medicare Modernization Act of 2003, prohibits Medicare Part D from covering drugs "when used for anorexia, weight loss, or weight gain." This exclusion applies categorically — it does not depend on medical necessity, BMI, or any other clinical factor. For most of Wegovy's existence, this meant Medicare beneficiaries simply could not get Wegovy covered, regardless of how clearly they met the medical criteria.

The 2024 cardiovascular indication exception

On March 8, 2024, the FDA approved a new indication for Wegovy: reducing the risk of major adverse cardiovascular events (MACE) — cardiovascular death, nonfatal heart attack, and nonfatal stroke — in adults with established cardiovascular disease and either obesity (BMI ≥30) or overweight (BMI ≥27). This indication was based on the SELECT trial, which followed about 17,600 patients for an average of 3.3 years and found a roughly 20% relative risk reduction in major cardiovascular events on semaglutide compared to placebo.

Within weeks of the FDA approval, the Centers for Medicare and Medicaid Services (CMS) issued guidance clarifying that Medicare Part D plans are permitted, but not required, to cover Wegovy when it is prescribed for the cardiovascular indication rather than for weight loss. This is a significant carve-out from the statutory exclusion: the medication is the same, but the indication on the prescription matters for whether it can be covered.

To qualify for Medicare coverage of Wegovy under the cardiovascular indication, a patient generally needs:

• A documented diagnosis of obesity (BMI ≥30) or overweight (BMI ≥27)
• Established cardiovascular disease — typically a prior heart attack, stroke, or documented coronary artery disease, peripheral artery disease, or similar
• A prescription that explicitly references the cardiovascular indication, not just weight loss
• Prior authorization documenting the above
• Enrollment in a Part D plan that has chosen to cover Wegovy for this indication (not all do)

If your plan covers it, your out-of-pocket cost will depend on the plan's tier placement and the new Medicare Part D out-of-pocket cap (which capped beneficiary out-of-pocket spending at $2,000 per year starting in 2025 under the Inflation Reduction Act). For many qualifying patients, that cap effectively means $0 in out-of-pocket cost for the rest of the year once it is hit.

Medicare and weight loss alone

If you do not have established cardiovascular disease and want Wegovy purely for weight loss, Medicare will not cover it. Several bills have been introduced in Congress (the Treat and Reduce Obesity Act, or TROA) that would lift the statutory weight loss exclusion, but as of early 2026 none have passed. Until and unless the law changes, Medicare beneficiaries seeking Wegovy for weight loss must pay cash — typically through the NovoCare $499/month direct program.

Medicaid coverage by state

Medicaid coverage of anti-obesity medications is a state-by-state patchwork. Federal law neither requires nor prohibits state Medicaid programs from covering anti-obesity drugs — each state Medicaid agency makes its own decision about whether to include them on the preferred drug list (PDL).

As of early 2026, approximately 13 states cover at least one GLP-1 medication for obesity through Medicaid, although the specific drugs and the rules vary. States that have historically been more inclusive include:

• California (Medi-Cal) — limited coverage; quantity limits and prior authorization apply
• Massachusetts (MassHealth) — covers Wegovy with prior authorization
• Pennsylvania — covers GLP-1s for obesity with prior authorization
• Delaware — covers with prior authorization
• Virginia — covers GLP-1s for obesity in some plans
• Wisconsin — covers with stricter criteria
• Michigan, Minnesota, New Hampshire, Rhode Island — varying coverage

Most state Medicaid programs do not cover Wegovy for weight loss. Even in states that do, prior authorization is universally required, criteria are typically stricter than commercial plans, and step therapy through cheaper generic anti-obesity medications (such as phentermine) is common. The list of covered states changes from year to year as state budgets and legislative decisions shift, so verify with your state Medicaid agency.

Medicaid managed care organizations (MCOs) such as Molina, Centene, AmeriHealth Caritas, and others operate within the rules set by their state Medicaid agency. If your state covers GLP-1s for obesity, your MCO has to as well, but the prior authorization process and any quantity limits are managed by the MCO.

Tricare

Tricare, the health program for uniformed service members, retirees, and their families, generally does not cover Wegovy when prescribed for weight loss. Tricare's pharmacy formulary, managed by Express Scripts, does cover semaglutide under the Ozempic brand for type 2 diabetes when medical criteria are met, but the obesity indication is generally excluded.

Active duty service members and dependents who are seeking weight loss support through Tricare typically have access to:

• Structured weight management programs through military treatment facilities (MTFs)
• Nutrition counseling and behavioral health support
• Bariatric surgery in qualifying cases
• Some older anti-obesity medications when appropriate

If you are a Tricare beneficiary and want Wegovy for weight loss, your most realistic options are paying cash through the NovoCare direct program at $499/month or ordering online from our partner pharmacy with coupon WEGOVY2026 for 10% off the cash price. If you have established cardiovascular disease and are dual-eligible for Medicare, you may qualify for the Medicare cardiovascular pathway described above.

Prior authorization requirements and how to get approved

Almost every insurer that covers Wegovy at all requires prior authorization. Prior auth is the insurance company's way of confirming that the medication is being prescribed to a patient who meets the FDA-approved criteria and matches the plan's clinical policy. A complete and well-documented PA request is approved most of the time. An incomplete or rushed one is denied most of the time.

Typical prior authorization criteria

Across major insurers, the prior authorization criteria for Wegovy are remarkably consistent. Most plans require all of the following:

• BMI documentation: A BMI of 30 or higher, OR a BMI of 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease).
• Age: 18 or older for adult plans; some plans cover 12+ for the FDA-approved adolescent obesity indication.
• Prior weight loss attempts: Documentation of at least 6 months of supervised diet and exercise attempts that did not produce sustained, clinically meaningful weight loss. Office notes from the prescriber are usually acceptable; some insurers want enrollment records from a structured program.
• Prescription source: Written by a licensed physician (in some plans, a nurse practitioner or physician assistant working under a physician is acceptable).
• No contraindications: The patient has no personal or family history of medullary thyroid carcinoma, no MEN 2 syndrome, is not pregnant, and has no other absolute contraindication.
• Step therapy (some plans): Documented prior failure or intolerance of another anti-obesity medication (Saxenda, phentermine, Contrave, Qsymia).
• Reauthorization at renewal: Documentation of at least 5% body weight loss after the initial 6-12 month authorization period to continue coverage.

How to maximize the chance of approval

Patients who get approved on the first try usually do a few things right:

1. Bring documentation to the prescribing visit. Have records of your weight, BMI, blood pressure, cholesterol, and any prior weight loss programs you have tried. The prescriber can lift this directly into the prior auth submission.
2. Ask for the exact diagnosis codes. The PA submission will use ICD-10 codes — typically E66.01 (morbid obesity), E66.9 (obesity unspecified), or Z68 codes for BMI. Make sure your chart reflects accurate codes.
3. Document prior attempts in writing. A note in the chart that says "patient attempted Mediterranean diet and walking program for 8 months in 2024 with weight loss of 4 lbs" is much stronger than "patient has tried diet and exercise."
4. Reference the cardiovascular indication if it applies. If you have any history of heart attack, stroke, coronary artery disease, or peripheral artery disease, ask your prescriber to document that and reference the cardiovascular indication on the PA. This unlocks an additional pathway, including for Medicare.
5. Use a prescriber who has done it before. Endocrinologists, obesity medicine specialists, and busy primary care offices have submitted hundreds of Wegovy PAs and know exactly what each insurer wants. A first-time prescriber may miss details that cause an avoidable denial.

If you are filing the PA yourself or want to verify your prescriber's submission, ask for a copy of the prior auth request before it is submitted. You have the right to see what is being sent on your behalf.

What to do if insurance denies coverage

Denials happen. The most common reasons for an initial denial are missing documentation (especially of prior weight loss attempts), failure to meet the BMI threshold, a step therapy requirement that was not addressed, or the plan simply excluding weight loss medications as a category. The first thing to do after a denial is to find out why.

Every formal denial comes with a written explanation of benefits (EOB) or determination letter that states the specific reason. Read it carefully. If the reason is a fixable documentation gap, your prescriber can resubmit the PA with the missing information. If the reason is a categorical exclusion (the plan does not cover weight loss medications at all), no amount of additional documentation will change that — and you have a different decision to make.

For patients whose plan flatly excludes weight loss medications, the realistic options are:

• Switch plans during open enrollment if you have a choice and another plan covers Wegovy. Verify the formulary first.
• Pursue the cardiovascular indication if you have qualifying cardiovascular disease.
• Pay cash through NovoCare Pharmacy at $499/month — significantly less than retail and the same medication.
• Order online from our partner pharmacy and apply coupon WEGOVY2026 for 10% off the cash price. For many people, this is the fastest path from "denied" to "starting treatment" — shipped to your door.

How to appeal a denial

If your denial is based on a fixable issue and your plan does cover Wegovy in principle, you have the right to appeal. Insurance appeals reverse denials more often than most patients expect — especially when the appeal includes complete clinical documentation.

Step 1 — Internal appeal

The first level of appeal is an internal appeal with your insurance company. You generally have 180 days from the date of the denial to file. Your prescriber's office can usually file this on your behalf, and most do it routinely. The internal appeal should include:

• The original prior authorization request
• The denial letter
• A letter of medical necessity from your prescriber, explaining the clinical rationale
• Updated documentation of any criteria that were lacking the first time (BMI records, prior weight loss programs, comorbidity diagnoses)
• Relevant clinical guidelines (American Association of Clinical Endocrinology, Obesity Medicine Association, Endocrine Society) supporting the use of Wegovy in your situation
• If applicable, peer-reviewed evidence from the STEP trials or the SELECT cardiovascular outcomes trial

Internal appeals are typically decided within 30 days for standard cases or 72 hours for expedited cases.

Step 2 — External review

If the internal appeal is denied, you can request an external review. An independent review organization (IRO) — not the insurance company — looks at your case and makes a binding decision. External review is free to the patient and typically returns a decision within 45 days for standard cases. External reviewers reverse insurance denials in about 40% of cases nationally.

Practical appeal tips

• Keep copies of everything. Every letter, every fax confirmation, every phone call (with the rep's name and a reference number).
• Use the magic words. Phrases like "medically necessary," "FDA-approved indication," and "consistent with American Association of Clinical Endocrinology guidelines" carry weight in appeals.
• Get your prescriber engaged early. Letters of medical necessity from the prescriber are often the difference between a successful appeal and a failed one.
• Don't miss deadlines. If you miss the 180-day window for an internal appeal, you typically lose the right to appeal that denial entirely.
• Consider a peer-to-peer review. Many insurers offer prescribers the option to schedule a "peer-to-peer" phone call with a medical director at the insurance company. These calls reverse a meaningful share of denials.

For complex appeals, some patients hire patient advocates or use the free appeals assistance available through state insurance departments. Every state has a department of insurance that handles consumer complaints about denied claims.

How to get Wegovy without insurance

If insurance coverage is not an option — your plan excludes weight loss drugs, your appeal failed, or you do not have insurance at all — Wegovy is still accessible at meaningfully lower prices than retail. The two main routes:

• NovoCare Pharmacy direct self-pay: $499/month for any dose, paid directly to Novo Nordisk's mail-order pharmacy. This bypasses the insurance and PBM system entirely. Requires a valid US prescription. Detailed walkthrough in our cost guide.
• Order online from our partner pharmacy: apply coupon WEGOVY2026 for 10% off the cash price. A prescription is still required, which the partner pharmacy coordinates. The advantage is speed and simplicity — it ships to your door, with no insurance paperwork.

For a full breakdown of cash-pay pricing and how to compare options, see our Wegovy cost guide and savings and coupons guide. For pharmacy and online-ordering specifics, see our where to buy Wegovy guide. If you're considering future oral options, see our Wegovy pill guide. The full Wegovy patient guide covers everything else — how it works, side effects, dosing, results, and how it compares to Ozempic and Zepbound.

Frequently Asked Questions

Pokriva li osiguranje Wegovy?

Ovisi o vašem konkretnom planu. Mnogi komercijalni planovi osiguranja sada pokrivaju Wegovy za pacijente koji ispunjavaju medicinske kriterije (BMI ≥30 ili BMI ≥27 uz komorbiditet povezan s tjelesnom težinom), ali znatan broj planova i dalje potpuno isključuje lijekove za mršavljenje. Gotovo svaki plan koji pokriva Wegovy zahtijeva prethodno odobrenje. Najbrži način da to saznate jest da nazovete broj članske službe na poleđini svoje kartice osiguranja i pitate je li semaglutid (Wegovy) na vašoj listi lijekova i koji su uvjeti za prethodno odobrenje.

Koje osiguranje pokriva Wegovy za mršavljenje?

Nijedan osiguravatelj ne jamči pokriće na svim planovima. UnitedHealthcare, Aetna, Cigna, Anthem i mnogi planovi Blue Cross Blue Shield pokrivaju Wegovy za mršavljenje barem na nekim svojim komercijalnim planovima kada su ispunjeni kriteriji za prethodno odobrenje. Pokriće je najčešće na planovima velikih poslodavaca, a najrjeđe na individualnim tržišnim planovima te Medicare i Medicaid planovima. Neki samofinancirajući poslodavci izričito isključuju lijekove za mršavljenje čak i kada bi ih temeljni osiguravatelj inače pokrio.

Pokriva li United Healthcare Wegovy?

Mnogi komercijalni planovi UnitedHealthcarea pokrivaju Wegovy uz prethodno odobrenje, ali pokriće se razlikuje od plana do plana, a posebno od poslodavca do poslodavca. UnitedHealthcare obično svrstava Wegovy u razinu 3 (nepreferirani brend) i zahtijeva dokumentaciju o BMI-ju, komorbiditetima i prethodnim pokušajima mršavljenja. Planovi UnitedHealthcare Medicare Advantage općenito ne pokrivaju Wegovy za mršavljenje, ali ga mogu pokriti prema kardiovaskularnoj indikaciji za podobne pacijente.

Pokriva li Aetna Wegovy?

Većina komercijalnih planova Aetne uključuje Wegovy na svoju listu lijekova u razini 3 uz prethodno odobrenje. Aetna često zahtijeva postupnu terapiju, što znači da je pacijent morao prvo isprobati drugi pokriveni lijek za mršavljenje (poput Saxende ili fentermina) te da nije uspio s njim ili je imao neprihvatljive nuspojave. Samofinancirajući planovi poslodavaca kod Aetne mogu potpuno isključiti lijekove za mršavljenje.

Pokriva li Blue Cross Blue Shield Wegovy?

Blue Cross Blue Shield nije jedan osiguravatelj, već federacija od 33 neovisna nositelja licence, pa se pokriće dramatično razlikuje po saveznoj državi i planu. Mnogi BCBS planovi pokrivaju Wegovy uz prethodno odobrenje, dok su drugi (osobito neki planovi BCBS Massachusetts i BCBS North Carolina u razdoblju 2024. – 2025.) izričito ukinuli ili ograničili pokriće lijekova za mršavljenje. Uvijek provjerite konkretan BCBS subjekt koji je izdao vaš plan.

Pokriva li Medicare Wegovy?

Prema zakonu, Medicare Part D ne može pokriti lijekove propisane isključivo za mršavljenje. Međutim, nakon što je FDA u ožujku 2024. odobrio Wegovy za smanjenje velikih neželjenih kardiovaskularnih događaja kod odraslih s pretilošću i utvrđenom kardiovaskularnom bolešću, CMS je pojasnio da je Part D planovima dopušteno (iako nije obavezno) pokriti Wegovy za tu konkretnu kardiovaskularnu indikaciju. Pacijenti s pretilošću i dokumentiranom poviješću srčanog udara, moždanog udara ili bolesti perifernih arterija mogu ispunjavati uvjete. Pokriće samo za mršavljenje i dalje je isključeno.

Pokriva li Medicaid Wegovy?

Pokriće Wegovyja u sklopu Medicaida razlikuje se po saveznoj državi. Početkom 2026. otprilike 13 saveznih država pokriva GLP-1 lijekove za pretilost putem Medicaida, uključujući Massachusetts, Pennsylvaniju, Delaware, Kaliforniju (djelomično), Virginiju i Wisconsin. Većina državnih Medicaid programa i dalje isključuje lijekove za pretilost. Čak i u državama koje ga pokrivaju, prethodno odobrenje obično je potrebno, a kriteriji su stroži nego kod komercijalnog pokrića.

Pokriva li Tricare Wegovy?

Tricare općenito ne pokriva Wegovy kada je propisan za mršavljenje. Tricare pokriva semaglutid pod brendom Ozempic za dijabetes tipa 2 kada su ispunjeni medicinski kriteriji te može pokriti druge opcije protiv pretilosti putem posebnih programa upravljanja tjelesnom težinom. Aktivni pripadnici službe uključeni u strukturirani program upravljanja tjelesnom težinom putem vojnih zdravstvenih ustanova mogu imati pristup dodatnim opcijama.

Kako da mi osiguranje pokrije Wegovy?

Prvo, potvrdite da je Wegovy na vašoj listi lijekova pozivom članskoj službi ili pregledom dokumenata plana. Drugo, zamolite svog zdravstvenog djelatnika da podnese zahtjev za prethodno odobrenje koji dokumentira vaš BMI, sva stanja povezana s tjelesnom težinom (hipertenzija, dijabetes tipa 2, dislipidemija, apneja u snu, kardiovaskularna bolest) i vašu povijest prethodnih pokušaja mršavljenja (obično 6 mjeseci nadzirane prehrane i tjelovježbe). Treće, ako budete odbijeni, podnesite žalbu s dodatnom dokumentacijom. Većina odbijenica poništava se na žalbu kada je klinička dokumentacija potpuna.

Koji su tipični kriteriji za prethodno odobrenje Wegovyja?

Većina planova zahtijeva: BMI od 30 ili više, ili 27 ili više uz barem jedan komorbiditet povezan s tjelesnom težinom; dokumentaciju o najmanje 6 mjeseci nadzirane prehrane i tjelovježbe; recept od licenciranog liječnika; nepostojanje kontraindikacija poput osobne ili obiteljske povijesti medularnog karcinoma štitnjače ili sindroma MEN 2; te da pacijent mora imati 18 ili više godina (ili 12+ za pretilost adolescenata u planovima koji pokrivaju pedijatrijsku indikaciju). Neki planovi dodaju postupnu terapiju, zahtijevajući prethodni neuspjeh sa starijim lijekom protiv pretilosti.

Koliko košta Wegovy bez osiguranja?

Bez osiguranja, najjeftinija legitimna opcija je program samoplaćanja NovoCare Pharmacy izravno potrošaču po cijeni od $499 mjesečno za bilo koju dozu. Gotovinske cijene u maloprodajnim ljekarnama obično se kreću od $1,200 do $1,450 mjesečno. Također možete naručiti online iz naše partnerske ljekarne i primijeniti kupon WEGOVY2026 za 10% popusta na gotovinsku cijenu. Pogledajte naš vodič o troškovima za potpunu raščlambu.

Koliko traje prethodno odobrenje za Wegovy?

Standardne odluke o prethodnom odobrenju obično se izdaju u roku od 3 do 14 radnih dana od podnošenja. Mnogi osiguravatelji nude ubrzane preglede za hitne slučajeve koji vraćaju odluku u roku od 72 sata. Ako vaš plan traje dulje, vi ili vaš zdravstveni djelatnik možete zatražiti ubrzani pregled. Neki planovi sada koriste elektroničko prethodno odobrenje koje može vratiti odluke isti dan kada je popratna dokumentacija potpuna.